Condiciones de salud que Andrographis puede ayudar a apoyar.
Clinical trials of Andrographis extract (HMPL-004) in ulcerative colitis patients demonstrated significant reductions in abdominal pain scores among other clinical symptoms. A double-blind RCT (n=224) found 60% clinical response rate at the 1,800 mg/day dose versus 40% for placebo (p=0.0183). A second active-controlled trial versus 5-ASA also documented reduction in abdominal pain and distension scores.
Andrographolide and related diterpene lactones from A. paniculata demonstrate well-characterized antioxidant activity in vitro including in human cell lines, with evidence of free radical scavenging (DPPH, ROS), elevation of antioxidant enzymes (SOD, catalase, glutathione), and reduction of lipid peroxidation biomarkers. These are consistently documented across peer-reviewed mechanistic and pharmacological studies.
Andrographis paniculata contains andrographolide, which inhibits NF-κB and suppresses pro-inflammatory cytokines including IL-1β and TNF-α. A double-blind RCT (2009, Clinical Rheumatology) found a standardized Andrographis extract significantly reduced joint tenderness, swelling, and pain in rheumatoid arthritis patients compared to placebo.
Andrographis paniculata and its diterpene andrographolide have anti-inflammatory properties targeting NF-κB and reducing Th2-driven airway inflammation in preclinical asthma models. Andrographolide inhibits expression of pro-inflammatory cytokines including IL-4, IL-5, and IL-13 relevant to eosinophilic asthma, and is traditionally used in Ayurvedic and TCM medicine for respiratory conditions.
Andrographis paniculata and its active constituent andrographolide have demonstrated immunomodulatory effects in experimental autoimmune encephalomyelitis (EAE, a MS model), significantly reducing symptoms by blocking T-cell activation and autoantibody responses to myelin. Traditional use in South and Southeast Asian medicine for inflammatory conditions is well-established.
Andrographolide inhibits platelet aggregation in human platelet preparations in vitro, inhibiting both PAF-induced and thrombin-induced aggregation in a dose-dependent manner. A human study in 63 cardiac/cerebrovascular patients showed significant inhibition of ADP-induced platelet aggregation following A. paniculata extract administration.
Andrographis paniculata contains andrographolide and related diterpenes with evidence for blood pressure reduction in preclinical and some clinical studies. A crude extract containing 14-deoxy-11,12-didehydroandrographolide significantly lowers blood pressure through calcium channel blockade and ACE inhibition.
Human clinical studies show that Andrographis supplementation can lower HbA1c and fasting insulin in type 2 diabetic patients. An open-label trial in 20 T2DM patients found a 5.46% reduction in HbA1c (p<0.01) with escalating doses over 12 weeks. A separate clinical study of a combined Andrographis/Syzygium polyanthum extract in metformin-treated T2DM patients demonstrated improvements in fasting and postprandial glucose.
Andrographis paniculata has meaningful clinical evidence for acute respiratory tract infections including acute bronchitis. A 2023 systematic literature review (Pharmaceuticals, Basel) classified Andrographis among four herbal medicines with moderate-to-high quality clinical evidence for acute uncomplicated respiratory tract infections, acting via immunomodulation, antiviral, and antipyretic mechanisms. Multiple clinical trials and systematic reviews support its use.
Andrographis paniculata has strong evidence from systematic reviews for relieving symptoms of acute respiratory tract infections including bronchitis. Its active compound andrographolide acts via immunomodulation and antiviral/antibacterial effects. A 2023 systematic review confirmed its mechanistic and clinical plausibility for uncomplicated acute respiratory infections.
Clinical studies measuring lipid profiles in diabetic and hypertriglyceridemic patients have assessed total cholesterol, LDL, and HDL alongside andrographis treatment. Some trials report LDL reductions in animal models and preliminary human data, though results in human studies are inconsistent, with at least one trial showing no significant cholesterol change.
Andrographis paniculata and its primary bioactive compound, andrographolide, have demonstrated anti-inflammatory activity in both preclinical models and human clinical trials. The herb inhibits key inflammatory pathways, including NF-κB and MAPK/ERK, suppressing cytokines such as TNF-α, IL-1β, IL-6, and COX-2. Randomized controlled trials in chronic inflammatory conditions—specifically ulcerative colitis and rheumatoid arthritis—have produced clinically meaningful, if modest, results. Evidence is most robust for intestinal inflammation, with supportive but smaller signals in joint-based chronic inflammation.
Andrographis paniculata has one of the strongest clinical evidence bases of any herbal medicine for upper respiratory tract infections. A 2017 systematic review of 33 RCTs (7,175 patients) found significant symptomatic relief for acute RTIs. Multiple placebo-controlled trials with the SHA-10 extract showed significant reductions in cold symptoms beginning at day 2. It has been used in Indian and Chinese traditional medicine for colds and influenza for centuries.
Andrographis paniculata extract (standardized for andrographolide) has been tested in randomized controlled trials for mild-to-moderate active ulcerative colitis, showing remission and response rates comparable to mesalazine. It is also used in Ayurvedic and traditional Chinese medicine for gastrointestinal inflammatory conditions.
Andrographis paniculata has been used in TCM to treat fever and infections for centuries. A randomized double-blind trial found andrographis as effective as paracetamol for reducing fever in 152 pharyngotonsillitis patients. Its active constituent andrographolide demonstrates antipyretic effects comparable to acetaminophen in animal models via COX-2 inhibition.
Andrographis paniculata has been evaluated in two placebo-controlled RCTs for ulcerative colitis via its standardized extract HMPL-004, demonstrating superiority over placebo in inducing clinical remission and response. A 2013 systematic review of herbal IBD therapies confirms its placebo-controlled RCT evidence in UC.
Andrographis paniculata and its primary diterpene andrographolide have demonstrated anti-hyperglycemic and insulin-sensitizing effects in animal studies and limited clinical evidence. Andrographolide activates PPAR-γ and AMPK pathways, improves GLUT4 expression, and reduces hepatic gluconeogenesis. Traditional Ayurvedic and Thai medicinal use for metabolic conditions is documented.
Andrographis paniculata has extensive use in Ayurvedic, Chinese, and Southeast Asian traditional medicine for liver protection, hepatitis, and jaundice. Scientific studies demonstrate andrographolide prevents hepatotoxin-induced liver injury by reducing oxidative stress, elevating glutathione, and inhibiting inflammatory mediators. Animal studies confirm hepatoprotective and antioxidant action against BHC and CCl4-induced liver damage.
Andrographis paniculata is widely used in Asian traditional medicine for respiratory infections and is supported by clinical evidence for reducing symptoms in viral upper respiratory infections. Its active compound andrographolide has demonstrated anti-inflammatory and antiviral properties relevant to lung and airway health.
Andrographis (Andrographis paniculata) is widely used in integrative Lyme disease protocols for its potent anti-inflammatory and immune-modulating properties via andrographolide. While a 2020 Johns Hopkins in vitro study found it did not directly inhibit B. burgdorferi, it is included in a comprehensive 2023 PMC review of 18 Lyme-relevant herbs. Traditional and clinical use focuses on immune support and anti-inflammatory action for persistent Lyme symptoms.
Clinical trial evidence for URTI includes reduction of mucus and airway congestion as documented outcomes. Andrographis is recognized in traditional Chinese medicine for 'clearing heat' from the lungs and resolving phlegm. The WHO's documented clinical indications include bronchitis and sinusitis, conditions characterized by excess mucus production.
Andrographis paniculata is a traditional Ayurvedic and Chinese medicine antiparasitic with documented in vitro and animal model activity against Plasmodium falciparum, Leishmania, and Trypanosoma. A 2023 review identified it among the most popular Ayurvedic antiparasitic plants.
Andrographis paniculata has been studied in RCTs and a systematic meta-analysis for acute respiratory tract infections, demonstrating significant improvement in cough, sore throat, and overall symptoms versus placebo. A retrospective cohort study in Thailand examined its association with reduced pneumonia risk in mild COVID-19 patients. Andrographolide, its active compound, showed significant anti-bacterial pneumonia effects in animal models via pulmonary delivery and by suppressing NF-κB-driven lung inflammation.
Used in Ayurvedic and Scandinavian herbal medicine for treating infectious illness and supporting recovery. A meta-analysis of 33 RCTs demonstrated Andrographis relieves inflammatory symptoms and shortens duration of upper respiratory illness including cough, sore throat, and sick leave. Its andrographolide inhibits cytokine storm mediators relevant to post-infectious inflammation.
Andrographis (Andrographis paniculata) has clinical trial evidence for reducing symptom severity and duration in viral respiratory illness. A Thai RCT in mild-to-moderate COVID-19 found that 60 mg extract three times daily improved cough within days and led to full recovery within 3 weeks. It also significantly reduced the inflammatory cytokine interleukin-1 beta by day 5.
Andrographis paniculata and its active constituent andrographolide have anti-inflammatory and immunomodulatory effects relevant to RA. ConsumerLab describes clinical evidence showing andrographis can help relieve pain and stiffness of RA. The branded ParActin extract has been specifically evaluated in RA clinical trials.
Andrographis is one of the most clinically studied herbs for upper respiratory tract infections (URTIs). Multiple RCTs and systematic reviews demonstrate significant reduction in URTI symptom severity and duration compared to placebo. The WHO formally lists prophylaxis and treatment of common cold, sinusitis, bronchitis, and pharyngotonsillitis among its documented clinical uses.
Andrographis paniculata has clinical evidence from multiple RCTs for reducing upper respiratory tract infection symptoms including nasal congestion and rhinitis. A 2023 PMC systematic review confirmed mechanistic evidence for immunomodulation and anti-inflammatory effects in acute URTIs. The ESCOP and European Pharmacopoeia recognize it for upper respiratory symptom relief including nasal congestion.
A double-blind, placebo-controlled study of the Andrographis paniculata combination product Kan Jang in 185 adults with acute URTIs including sinusitis found treatment reduced cold symptoms and inflammatory symptoms of sinusitis. Andrographis is used in traditional Ayurvedic and Chinese medicine for respiratory infections.
Andrographis paniculata has clinical trial evidence for upper respiratory tract infections including pharyngitis. A Cochrane review update and multiple RCTs found Andrographis preparations significantly reduced the severity and duration of acute upper respiratory symptoms, with specific effects on sore throat reported. The active compound andrographolide has anti-inflammatory and antiviral properties.
Andrographis paniculata has been studied in clinical trials for acute respiratory tract infections including tonsillitis. A 1996 trial compared it to penicillin for sore throat with comparable recovery rates. A systematic review and meta-analysis confirmed it shortens sore throat duration and ARTI symptoms. Traditional Chinese medicine uses it specifically for sore throat and swollen tonsils at 3–6 g/day.
A clinical study in 60 patients with modest hypertriglyceridemia found that andrographolide extract at 120 mg/day improved serum triglyceride levels. Animal studies further corroborate hypolipidemic effects on triglycerides, and clinical trial data in T2DM patients has also assessed triglyceride outcomes.
Andrographis paniculata has robust clinical evidence for URTI treatment. A DARE-assessed systematic review of 7 controlled trials (n=896) found it significantly superior to placebo for uncomplicated URTI symptom relief. A double-blind RCT of KalmCold (200 mg/day, n=223) showed significant improvement in all nine measured URTI symptoms by day 5 vs. placebo.
Andrographis paniculata and its primary diterpene andrographolide have demonstrated antiviral and immunomodulatory activity in multiple clinical trials against respiratory viruses. The plant is used in Ayurvedic and Traditional Chinese Medicine as an anti-infective. RCTs show significant reduction in cold and flu symptom scores and duration.
Andrographis has well-documented traditional use for diarrhea and dysentery across Ayurveda, Traditional Chinese Medicine, and Southeast Asian traditional medicine. It is described in TCM for 'toxic-heat type diarrhea' and has been used historically for dysentery. Modern preclinical data supports antimicrobial and anti-inflammatory actions that may underlie this traditional use.
Andrographis is regarded in traditional medicine as a cholagogue — a bitter herb that stimulates bile production and flow, supporting gallbladder function. Its extremely bitter taste (earning the name 'King of Bitters') is associated in Ayurvedic theory with digestive and hepatobiliary stimulation. Scientific documentation of this effect in human clinical trials is absent.
Traditional use of Andrographis for lower urinary tract infections and urinary health is documented in TCM, Ayurveda, and Southeast Asian traditional medicine. It is listed among classical TCM indications for 'toxic heat' affecting the kidneys and urinary tract. No human RCTs specifically for UTI have been identified.
Documented traditional use in TCM and Ayurveda for lower urinary tract infections and 'damp heat' affecting the kidneys. Andrographolide's antimicrobial properties may support its historical use. Preclinical nephroprotective evidence exists but human clinical trial data for UTI specifically is absent.
Andrographis has well-documented traditional use as a topical wound remedy in TCM for sores, ulcers, burns, carbuncles, and scalds. Preclinical animal studies confirm accelerated wound closure and enhanced collagen deposition with topical A. paniculata extract. No human clinical trials for wound healing have been identified.
Volver